
Non-Sponsored Content
Everolimus oral suspension approved for adjunctive treatment of TSC-associated partial-onset seizures
By: News Feed | Last updated: 10th April 2018 | In: Genitourinary Cancer, Oncology, US FDA Onc\Haem Approvals
Article Keywords
Afinitor, astrocytoma, everolimus, FDA, mTor, Novartis, paediatric, SEGA, seizures, TSC
On April 10, the FDA approved everolimus tablets for oral suspension (Afinitor Disperz®, Novartis) for the adjunctive treatment of adult and pediatric patients ≥2 years with tuberous sclerosis complex (TSC)-associated partial-onset seizures.
Everolimus is also approved for two other forms of TSC:
- TSC-associated subependymal giant cell astrocytoma (SEGA);
- TSC-associated renal angiomyolipoma.
Disclaimer
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2018 MediPaper Medical Communications Ltd.
YOU MAY ALSO LIKE




































































Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients











































































































© Copyright 2018 MediPaper Medical Communications Ltd.
Leave a Reply
Want to join the discussion?Feel free to contribute!